Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 14: 653-655

Author(s): Cooke JP, Tsao PS



NO is a potent vasodilator that activates soluble guanylate cyclase, thereby increasing intracellular levels of cyclic GMP. In addition, NO exerts an inhibitory influence on cell proliferation and adhesion. The proliferation of vascular smooth muscle cells or lymphocytes in culture is inhibited by exogenous NO donors as well as endogenous NO.Platelet adhesion and aggregation as well as monocyte adhesion and chemotaxis are negatively regulated by this molecule. These in vitro studies indicate that NO suppresses a number of key processes that are involved in atherogenesis. It seems logical, therefore, that a reduction in the activity of vascular NO would promote atherogenesis. Indeed, one of the earliest abnormalities to occur in hypercholesterolemic animals and humans is a reduction in the activity of vascular NO, as manifested by impaired endothelium-dependent vasodilation. This occurs well before any structural changes in the vessel wall. This impairment in endothelium-dependent vasodilation is reversible in hypercholesterolemic animal models and humans by intravenous infusion of the NO precursor L-arginine. The effect of L-arginine to normalize endothelium-dependent vasodilation is likely due to its metabolism to NO, since the effect is not mimicked by D-arginine (which is not a substrate for NO synthase).Chronic administration of supplemental dietary arginine to hypercholesterolemic rabbits is also associated with an improvement in endothelium-dependent vasodilation. The sustained enhancement of vascular NO activity is paralleled by a striking inhibition of intimal lesion formation in these animals. Dietary arginine also exerts an inhibitory effect on neointimal lesion formation after balloon injury in this animal 

Similar Articles

Costs and duration of care for lower extremity ulcers in patients with diabetes

Author(s): Holzer SE, Camerota A, Martens L, Cuerdon T, Crystal-Peters J, et al.

The L-arginine-nitric oxide pathway

Author(s): Moncada S, Higgs A

Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy

Author(s): Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, et al.

eNOS gene polymorphism association with retinopathy in type 1 diabetes

Author(s): Bazzaz JT, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, et al.

eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy

Author(s): Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, et al.

Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with type 2 diabetes and its chronic complications

Author(s): Mehrab-Mohseni M, Tabatabaei-Malazy O, Hasani-Ranjbar S, Amiri P, Kouroshnia A, et al.

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Author(s): Wild S, Roglic G, Green A, Sicree R, King H

Ethnic India: a genomic view, with special reference to peopling and structure

Author(s): Basu A, Mukherjee N, Roy S, Sengupta S, Banerjee S, et al.

Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians

Author(s): Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Sud K, et al.

Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction

Author(s): Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, et al.

Endothelial nitric oxide synthase gene is positively associated with essential hypertension

Author(s): Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, et al.

Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia

Author(s): Yoshimura T, Yoshimura M, Tabata A, Shimasaki Y, Nakayama M, et al.